Intervention(s) and comparator(s)	Participants included in analysis [N]	Participants discontinuing study due to adverse events [N]	Participants discontinuing study due to adverse event [%]	Participants hospitalised [N]	Participants hospitalised [%]	Participants with outpatient treatment [N]	Participants with outpatient treatment [%]
Hero 2005	I: letrozole	16	0	0	0	0	0	0
	C: placebo	15	1	7	1	7	0	0
Mauras 2008	I: anastrozole + GH	26	0	0	4a	15	0	0
	C: placebo + GH	26	0	0	0	0	0	0
Salehpour 2010	I1: letrozole	31	0	0	‐	‐	‐	‐
	I2: oxandrolone	30	0	0	‐	‐	‐	‐
	C: placebo	30	0	0	‐	‐	‐	‐
Wickman 2001	I: letrozole + testosterone	11	0	0	‐	‐	‐	‐
	C1: placebo + testosterone	12	0	0	‐	‐	‐	‐
	C2: no treatment	10	0	0	‐	‐	‐	‐
"‐" denotes not reported a4 participants admitted to hospital, 1 participant had 4 separate admissions GH: growth hormone; N: number of participants